SGI-110 in Combination With Carboplatin in Ovarian Cancer - Full Text View - ClinicalTrials.gov

A 2-part, Phase 1-2 controlled, open-label, randomized study in patients with platinum-resistant recurrent ovarian cancer. In Part 1, patients will receive SGI-110 and carboplatin. The optimum dose will be identified in Part 1 based on safety and efficacy. In Part 2, patients will be randomized to receive the dose identified in Part 1 plus carboplatin or one of three treatment of choice at the discretion of the investigator. The treatment of choice consists of topotecan, pegylated liposomal doxorubicin, or paclitaxel.

http://clinicaltrials.gov/ct2/show/NCT01696032?term=ovarian+cancer&recr=Open&lup_s=08%2F29%2F2012&lup_d=30

Sent from my iPhone